Joint Ventures: Aiming for Targeted First-Line Therapy in Early RA at EULAR 2026ByJack Arnold, MBBS, MRCP, PhD,Laurence Duquenne, MD, PhDJune 23rd 2026
Fibroblast TGFβ Signaling in Vascular Niches May Drive Treatment-Refractory RA, With Kevin Wei, MD, PhDByKevin Wei, MD, PhDApril 23rd 2026
Abatacept May Delay RA Onset for Up to 4 Years in At-Risk Individuals, With Andrew Cope, MD, PhDByAndrew Cope, MDApril 20th 2026
Precision Medicine and the Pursuit of Remission in RA and PsA, with Arthur Kavanaugh, MDByArthur Kavanaugh, MDFebruary 20th 2026
GLP-1s and Beyond: Integrating Metabolic Health into PsA and RA Care, with Eric Ruderman, MDByEric M. Ruderman, MDFebruary 18th 2026